GLP-1 receptor agonists are now first-line therapy in US guidelines for the management of type-2 diabetes and are approved at higher doses for weight loss.
One potential mechanism of action for the dramatic weight reductions involves blocking the reward pathway in the brain, as anecdotally people lose interest in eating. This is supported by some study participants reporting a similar lack of interest in other addictive behaviour, for example reducing alcohol use.
Read the full report by Simon Collins, HIV i-Base here.
Source : HIV i-Base
Related HIV and Co-Infections News
-
MedPage Today: Antidepressant reduces meth addiction in trial
-
[Press release] NIH: Clinical trial results support use of weekly extended-release buprenorphine for treatment of opioid use disorder during pregnancy
-
HIV i-Base: GLP-1 receptor agonists reduce substance use disorder: a role for addiction to chemsex drugs?
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.